Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
    30 August 2026

    FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

    The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.

  • FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
    30 August 2026
    FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

    The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya offers patients an important new alternative by providing an effective oral treatment option.

  • MPSC Cancels Drug Inspector Recruitment After Probe Finds Question Paper Leak Benefit
    26 August 2026
    MPSC Cancels Drug Inspector Recruitment After Probe Finds Question Paper Leak Benefit

    The Maharashtra Public Service Commission (MPSC) has cancelled the recruitment process for Drug Inspector, Group-B posts under the Food and Drug Administration Department, citing concerns over the integrity of the screening examination.

    The recruitment advertisement, No. 116/2025, was issued on July 29, 2025. The screening examination was conducted offline on March 22, 2026, at examination centres located in six divisional headquarters across Maharashtra. The result was declared on June 12, 2026, with 506 candidates qualifying for interviews.

  • USFDA Inspection at Aurobindo Pharma’s Lannett Facility Concludes With Four Observations
    24 August 2026
    USFDA Inspection at Aurobindo Pharma’s Lannett Facility Concludes With Four Observations

    A routine inspection by the United States Food and Drug Administration (US FDA) at Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma USA, Inc., has concluded with four observations.

    The inspection was conducted at Lannett Company’s manufacturing facility in Seymour, Indiana, USA, from August 17 to August 21, 2026. According to the company’s regulatory filing, the inspection was carried out as part of the US FDA’s routine inspection process.

  • Robot-assisted surgery shows clinical advantages over laparoscopic surgery for gastric cancer
    24 August 2026
    Robot-assisted surgery shows clinical advantages over laparoscopic surgery for gastric cancer
    Surgery remains the primary curative treatment for gastric cancer, with laparoscopic gastrectomy (LG) established as a standard minimally invasive approach. While LG offers faster recovery than open surgery, it remains technically demanding because surgeons must operate within a confined space using rigid instruments that can amplify hand tremors.
  • CDSCO Flags 239 Drug Samples as Not of Standard Quality in July 2026 Alert
    24 August 2026
    CDSCO Flags 239 Drug Samples as Not of Standard Quality in July 2026 Alert

    The Central Drugs Standard Control Organization (CDSCO) has released its July 2026 Not of Standard Quality (NSQ) drug alert, listing a large number of medicine samples that failed to meet specified quality standards during testing by state and CDSCO laboratories.

  • PCI Unveils Four Major Initiatives to Transform Pharmacy Education, Research and Career Opportunities
    22 August 2026
    PCI Unveils Four Major Initiatives to Transform Pharmacy Education, Research and Career Opportunities

    The Pharmacy Council of India (PCI) has introduced four major initiatives aimed at strengthening pharmacy education, research and professional development in India. The initiatives were unveiled at CAPSULE 4.0 and include the new M.Pharm (Medical Devices) programme, Research Promotion Scheme (RPS), Doctoral Fellowship Scheme (PDFS) and Pharmacy Awards.

  • TDB Backs Vadodara Startup OrthoGraft to Commercialize Advanced Biological Dressings for Difficult Wounds
    21 August 2026
    TDB Backs Vadodara Startup OrthoGraft to Commercialize Advanced Biological Dressings for Difficult Wounds
    The Technology Development Board (TDB), under the Department of Science & Technology (DST), Government of India, has extended financial assistance to Vadodara-based medical device startup OrthoGraft Pvt. Ltd. to establish a production facility for advanced tissue-derived biological dressings aimed at wound-care applications
  • A smart cancer drug developed by India, could replace chemotherapy
    20 August 2026
    A smart cancer drug developed by India, could replace chemotherapy

    New ‘Smart’ Cancer Drug Targets Tumor Cells While Sparing Healthy Tissue. Scientists in India have developed a promising experimental cancer drug designed to activate mainly inside cancer cells, potentially offering a more selective approach than conventional chemotherapy.

  • FDA Approves Second Treatment for Rare “Stone Man” Disease
    20 August 2026
    FDA Approves Second Treatment for Rare “Stone Man” Disease

    The U.S. Food and Drug Administration (FDA) has approved Pasatru (garetosmab-grts) as a treatment for adults with fibrodysplasia ossificans progressiva (FOP), an extremely rare genetic disorder in which muscles, tendons and ligaments can gradually turn into bone. The approval makes Pasatru the second FDA-approved treatment for FOP, providing another therapeutic option for people affected by this debilitating condition.

Subscribe to Pharma News